Market Closed -
Nasdaq
02:00:01 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
29.79
USD
|
+2.72%
|
|
+8.13%
|
-48.42%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
336.6
|
1,394
|
736.5
|
-
|
-
|
Enterprise Value (EV)
1 |
142
|
1,394
|
370.6
|
374.9
|
407.7
|
P/E ratio
|
-0.44
x
|
-16.9
x
|
-6.73
x
|
-5.81
x
|
-4.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
230
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
127
x
|
EV / EBITDA
|
-
|
-15.3
x
|
-3.36
x
|
-2.39
x
|
-2.4
x
|
EV / FCF
|
-
|
-
|
-3.71
x
|
-3.54
x
|
-3.28
x
|
FCF Yield
|
-
|
-
|
-27%
|
-28.3%
|
-30.5%
|
Price to Book
|
-
|
-
|
1.91
x
|
1.83
x
|
2.69
x
|
Nbr of stocks (in thousands)
|
16,923
|
24,140
|
24,721
|
-
|
-
|
Reference price
2 |
19.89
|
57.76
|
29.79
|
29.79
|
29.79
|
Announcement Date
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
3.2
|
EBITDA
1 |
-
|
-
|
-91.02
|
-110.3
|
-156.6
|
-169.8
|
EBIT
1 |
-
|
-47.48
|
-91.12
|
-132.9
|
-146.3
|
-171.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-5,352.88%
|
Earnings before Tax (EBT)
1 |
-
|
-46.83
|
-76.33
|
-111.2
|
-134.9
|
-159.9
|
Net income
1 |
-35.97
|
-46.83
|
-76.43
|
-111.7
|
-137.4
|
-174.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-5,444.13%
|
EPS
2 |
-4.490
|
-45.05
|
-3.420
|
-4.427
|
-5.123
|
-6.310
|
Free Cash Flow
1 |
-
|
-
|
-
|
-99.9
|
-106
|
-124.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-3,885.42%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/09/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-15.02
|
-25.12
|
-17.33
|
-18.96
|
-29.71
|
-26.96
|
-26.69
|
-27.27
|
-33.39
|
-25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-11.24
|
-22.76
|
-15.92
|
-14.1
|
-23.55
|
-24.44
|
-24.92
|
-25.51
|
-31.62
|
-25
|
Net income
1 |
-16.15
|
-11.24
|
-22.78
|
-15.95
|
-14.12
|
-23.58
|
-24.96
|
-25.5
|
-26.27
|
-31.4
|
-25
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.860
|
-40.91
|
-1.200
|
-0.7400
|
-0.5800
|
-0.9700
|
-1.037
|
-1.072
|
-1.110
|
-1.247
|
-1.120
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/11/22
|
31/03/23
|
15/05/23
|
11/08/23
|
09/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
195
|
-
|
366
|
362
|
329
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-99.9
|
-106
|
-124
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-24.5%
|
-29.3%
|
-33.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
15.60
|
16.30
|
11.10
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.15
|
-
|
0.15
|
2.55
|
5.05
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
157.81%
|
Announcement Date
|
02/09/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
29.79
USD Average target price
57.11
USD Spread / Average Target +91.71% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.42% | 736M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|